Scilex Holding Company Announces Receipt of Notice from Nasdaq
PALO ALTO, Calif., Nov. 22, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or the “Company”), an innovative...
Pharmaceutical
Addex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Indivior selected GABA B PAM drug candidate for development in substance use disorders (SUD) and starts IND enabling studies Ad...
HUTCHMED Announces Launch by Takeda of FRUZAQLA® (fruquintinib) in Japan
— Launch follows approval by Japanese Ministry of Health, Labour and Welfare in September 2024 — — Milestone payment to be made to...
BioAdaptives, Inc. Announces 5 Unique Products Ready for Phased Entry Into the Nutritional Marketplace
LAS VEGAS, Nov. 21, 2024 (GLOBE NEWSWIRE) -- BioAdaptives Inc. (OTC: BDPT) ushered in a new direction by appointing James...
Hemogenyx Pharmaceuticals PLC Announces IRB Approval for Phase I Clinical Trial
Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK / ACCESSWIRE / November 22, 2024...
Sonoma Pharmaceuticals Announces Relaunch of Prescription Dermatology and Eye Care Product Lines in the United States
BOULDER, CO / ACCESSWIRE / November 21, 2024 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing...
Protagonist Announces Nomination of PN-881, a Potential Best-in-Class Oral Peptide IL-17 Antagonist Development Candidate
Oral peptide with biologics-like high potency and spectrum of activity against three therapeutically relevant dimeric forms of IL-17 (AA, AF...
Genpact Announces Renewed Partnership with Ferring Pharmaceuticals
Renewed multi-year partnership to support Ferring Pharmaceuticals' operations in response to rapid business growth NEW YORK, Nov. 21, 2024 /PRNewswire/...
Evogene Reports Third Quarter 2024 Financial Results
Conference call and webcast: today, November 21, 2024, 9:00 am ET Financial Highlights: In the first nine months of 2024,...
Hexaware Launches QCaaS in Partnership with Archimedis Digital
Setting a Quality & Compliance Foundation for Life Sciences Firms to Leverage Technological Advancements ISELIN, N.J., Nov. 21, 2024 /PRNewswire/...
Outcomes4Me and the National Comprehensive Cancer Network (NCCN) Expand Collaboration to Improve Outcomes for Patients Diagnosed with Prostate Cancer
Enhanced integration fuels the rapid growth of this first-of-its kind platform and related initiative between Outcomes4Me and NCCN, leveraging technology to...
Gaining Momentum, Biodexa is Advancing Two Recent Acquisitions Through the Clinic
CARDIFF, UK / ACCESSWIRE / November 21, 2024 / Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), an acquisition-focused clinical-stage biopharmaceutical company focused on...
Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
MIAMI, FL / ACCESSWIRE / November 21, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) ("Telomir" or the "Company"), an emerging leader...
GRI Bio Showcases GRI-0621’s Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)
Workshop, poster and oral presentation of data given as part of the 8th Annual Antifibrotic Drug Development (AFDD) Summit Data...
Dyadic Receives $3 Million Grant to Develop Cost-Effective Monoclonal Antibodies for RSV and Malaria Using C1 Platform Technology
Grant Received from the Bill & Melinda Gates Foundation to Fund Development of Affordable TherapeuticsJUPITER, Fla., Nov. 21, 2024 (GLOBE...
Biomerica Secures Three Key International Patents for inFoods® Technology to Address GERD, Crohn’s Disease, and Ulcerative Colitis
New patents position Biomerica to address multi-billion-dollar markets in Europe, including GERD ($4 billion+), Crohn’s Disease ($2.5 billion+), and Ulcerative...
Palisade Bio to Present Preclinical Results for PALI-2108 Demonstrating Engagement of Key Fibrotic Pathways of Crohn’s Disease and Ulcerative Colitis (UC)
Data to be presented at the 8th Annual Antifibrotic Drug Development (AFDD) Summit PALI-2108 may offer a solution for fibrostenotic...
Umoja Biopharma Appoints Scott Myers as Chairman of its Board of Directors
SEATTLE, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Umoja Biopharma, Inc. (Umoja), the clinical-stage leader of in vivo and off-the-shelf therapies...
Biolojic Design Appoints Neal Curran as Chief Business Officer
REHOVOT, Israel and WASHINGTON, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Biolojic Design, a biotechnology company that uses computational biology and...
Apollomics’ Announces Shareholder Approval and Effective Date for 1-for-100 Reverse Share Split
The Company's class A ordinary shares will begin trading on a split-adjusted basis on November 25, 2024FOSTER CITY, Calif., Nov....